(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Major Depressive Disorder
Explore 198 assets in Major Depressive Disorder →Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Western University, Canada
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07569198CT.gov Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | — | Not Yet Recruiting | — | — | — |
NCT06781697CT.gov InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | — | Not Yet Recruiting | — | — | — |
NCT07139106CT.gov Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | — | Not Yet Recruiting | — | — | — |
NCT06788249CT.gov Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | — | Recruiting | — | — | — |
NCT07396272CT.gov A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression | — | Active Not Recruiting | — | — | — |
NCT07307768CT.gov Ketamine Biomarker Validation | — | Not Yet Recruiting | — | — | — |
NCT07247370CT.gov Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL) | — | Not Yet Recruiting | — | — | — |
NCT07088380CT.gov Ketamine Augmentation of ECT in Treatment-Resistant Depression | — | Recruiting | — | — | — |
NCT06620276CT.gov ACT_for Alcohol Use Disorder and Depression | — | Recruiting | — | — | — |
NCT05603104CT.gov Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | — | Recruiting | — | — | — |
Show 116 more trialsShow fewer
NCT06891300CT.gov Understanding and Treating Suicidal Ideation With Ketamine | — | Recruiting | — | — | — |
NCT06668571CT.gov Intravenous Ketamine for Treatment-Resistant Depression | — | Recruiting | — | — | — |
NCT06559826CT.gov Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression | — | Recruiting | — | — | — |
NCT06508710CT.gov Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients | — | Recruiting | — | — | — |
NCT06752759CT.gov Nebulized Ketamine for the Treatment of Major Depressive Disorder | — | Recruiting | — | — | — |
NCT06402955CT.gov Imaging Depression in Parkinson's Disease | — | Recruiting | — | — | — |
NCT05973851CT.gov The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. | — | Recruiting | — | — | — |
NCT06278779CT.gov Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | — | Recruiting | — | — | — |
NCT06410599CT.gov Pharmacologic Treatment Augmentation in Chronic Depression | — | Recruiting | — | — | — |
NCT06228391CT.gov Ketamine Treatment for PTSD and MDD in TBI | — | Not Yet Recruiting | — | — | — |
NCT06213324CT.gov Neural Circuit Effects of Ketamine in Depression | — | Recruiting | — | — | — |
NCT06725277CT.gov The OBSERVE Protocol | — | Recruiting | — | — | — |
NCT05625555CT.gov Predictors of Intravenous Ketamine Response in TRD | — | Active Not Recruiting | — | — | — |
NCT06480500CT.gov i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | — | Recruiting | — | — | — |
NCT06480201CT.gov Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression | — | Suspended | — | — | — |
NCT06138691CT.gov KET-RO Plus RO DBT for Treatment Resistant Depression | — | Completed | — | — | — |
NCT06070766CT.gov RIVER At Home Ketamine Protocols | — | Recruiting | — | — | — |
NCT05915013CT.gov Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response | — | Recruiting | — | — | — |
NCT05786066CT.gov The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | — | Recruiting | — | — | — |
NCT05506462CT.gov An EEG Study of Intravenous Ketamine for Major Depression Disorder | — | Unknown | — | — | — |
NCT05327699CT.gov Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine | — | Recruiting | — | — | — |
NCT05450432CT.gov Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | — | Recruiting | — | — | — |
NCT05464264CT.gov Auditory MMN EEG in TRD in Response to Ketamine | — | Unknown | — | — | — |
NCT05565352CT.gov Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD) | — | Enrolling By Invitation | — | — | — |
NCT05809609CT.gov Glutamate Emotion Memory Study | — | Unknown | — | — | — |
NCT05320107CT.gov The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects | — | Unknown | — | — | — |
NCT05046184CT.gov Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets | — | Completed | — | — | — |
NCT07099235CT.gov Chart Review of Patients Undergoing Ketamine Treatments for Depression | — | Completed | — | — | — |
NCT05045378CT.gov Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression | — | Completed | — | — | — |
NCT05193318CT.gov KAP for Depression in Abstinent Opioid Users | — | Terminated | — | — | — |
NCT05870501CT.gov Synaptic Imaging and Network Activity in Treatment Resistant Depression | — | Completed | — | — | — |
NCT04939649CT.gov Ketamine As an Adjunctive Therapy for Major Depression (2) | — | Completed | — | — | — |
NCT04850911CT.gov Reward Emotion Learning and Ketamine Study | — | Unknown | — | — | — |
NCT05383313CT.gov Psilocybin Versus Ketamine in Treatment-Resistant Depression | — | Unknown | — | — | — |
NCT05249309CT.gov Naturalistic Study of Ketamine in the Treatment of Depression | — | Unknown | — | — | — |
NCT04480918CT.gov University of Iowa Interventional Psychiatry Service Patient Registry | — | Recruiting | — | — | — |
NCT04504175CT.gov Ketamine for Older Adults Pilot | — | Completed | — | — | — |
NCT04091971CT.gov Ketamine Treatment Effects on Synaptic Plasticity in Depression | — | Completed | — | — | — |
NCT04587778CT.gov Imaging Neural Correlates of Ketamine Using PET/MR | — | Unknown | — | — | — |
NCT04101474CT.gov Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality | — | Completed | — | — | — |
NCT04399070CT.gov The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT) | — | Unknown | — | — | — |
NCT03973268CT.gov Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression | — | Recruiting | — | — | — |
NCT04260607CT.gov Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department | — | Terminated | — | — | — |
NCT04226963CT.gov A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders | — | Completed | — | — | — |
NCT04209296CT.gov Chart Review of Patients Undergoing Ketamine Infusions | — | Completed | — | — | — |
NCT04266288CT.gov Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department | — | Completed | — | — | — |
NCT04032301CT.gov Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans | — | Completed | — | — | — |
NCT04471818CT.gov Ketamine or Placebo in Patients With Major Depression and Advanced Cancer | — | Completed | — | — | — |
NCT03861988CT.gov Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery | — | Completed | — | — | — |
NCT03051945CT.gov Endogenous Opioid Modulation by Ketamine | — | Withdrawn | — | — | — |
NCT04099771CT.gov Ketamine for Mood Disorders With Suicidal Ideation | — | Unknown | — | — | — |
NCT03977675CT.gov The Role of HNKs in the Antidepressant Effect of Ketamine | — | Terminated | — | — | — |
NCT03573349CT.gov Ketamine Associated ACC GABA and Glutamate Change and Depression Remission: | — | Active Not Recruiting | — | — | — |
NCT03367533CT.gov Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial | — | Completed | — | — | — |
NCT03742557CT.gov Evaluation of Schemes of Administration of Intravenous Ketamine in Depression | — | Unknown | — | — | — |
NCT03666390CT.gov Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide | — | Unknown | — | — | — |
NCT04021433CT.gov Ketamine for Treatment Resistant MDD | — | Unknown | — | — | — |
NCT03380442CT.gov Psilocybin and Depression | — | Unknown | — | — | — |
NCT03290963CT.gov Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine | — | Withdrawn | — | — | — |
NCT03256162CT.gov Ketamine as an Adjunctive Therapy for Major Depression | — | Completed | — | — | — |
NCT03272698CT.gov ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression | — | Recruiting | — | — | — |
NCT03156504CT.gov The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. | — | Completed | — | — | — |
NCT03065335CT.gov Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder | — | Recruiting | — | — | — |
NCT03113968CT.gov ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD) | — | Completed | — | — | — |
NCT03053830CT.gov Open Label Ketamine Treatment for Major Depressive Disorder in Veterans | — | Completed | — | — | — |
NCT02882711CT.gov The UTHealth Ketamine Project | — | Terminated | — | — | — |
NCT02935595CT.gov Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients | — | Completed | — | — | — |
NCT02772211CT.gov D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression | — | Unknown | — | — | — |
NCT03658330CT.gov Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder | — | Completed | — | — | — |
NCT02734602CT.gov Imaging SV2A in Mood Disorders | — | Active Not Recruiting | — | — | — |
NCT02644629CT.gov Intra-nasal vs. Intra-venous Ketamine Administration | — | Completed | — | — | — |
NCT02752724CT.gov Ketamine Anesthesia for Improvement of Depression in ECT | — | Completed | — | — | — |
NCT02544607CT.gov Ketamine for Depression: An MRI Study | — | Completed | — | — | — |
NCT02593643CT.gov Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | — | Completed | — | — | — |
NCT02661061CT.gov Ketamine for Relapse Prevention in Recurrent Depressive Disorder | — | Terminated | — | — | — |
NCT02422303CT.gov Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms | — | Terminated | — | — | — |
NCT02579928CT.gov Ketamine Infusion for Adolescent Depression and Anxiety | — | Completed | — | — | — |
NCT01613820CT.gov Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder | — | Withdrawn | — | — | — |
NCT02522377CT.gov Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression | — | Completed | — | — | — |
NCT02418195CT.gov miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome | — | Completed | — | — | — |
NCT02360280CT.gov Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression | — | Completed | — | — | — |
NCT02401139CT.gov Ketamine Trial for the Treatment of Depression | — | Completed | — | — | — |
NCT02659085CT.gov Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder | — | Completed | — | — | — |
NCT03609190CT.gov A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine | — | Completed | — | — | — |
NCT02461927CT.gov Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder | — | Completed | — | — | — |
NCT01920555CT.gov Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | — | Completed | — | — | — |
NCT02078817CT.gov Ketamine in Adolescents With Treatment-Resistant Depression | — | Completed | — | — | — |
NCT02219867CT.gov Ketamine Infusions for Major Depression Disorder | — | Unknown | — | — | — |
NCT02165449CT.gov Biomarkers of Fast Acting Therapies in Major Depression | — | Completed | — | — | — |
NCT02122562CT.gov Ketamine Alcohol (in Treatment-Resistant Depression) | — | Recruiting | — | — | — |
NCT01957410CT.gov A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder | — | Terminated | — | — | — |
NCT02037503CT.gov The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major Depression | — | Unknown | — | — | — |
NCT01868802CT.gov Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population | — | Unknown | — | — | — |
NCT01944293CT.gov Ketamine for Suicidality in Bipolar Depression | — | Completed | — | — | — |
NCT01935115CT.gov Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy | — | Completed | — | — | — |
NCT02048423CT.gov An Open Prospective Trial of IV Ketamine in Suicidal Adolescents | — | Unknown | — | — | — |
NCT01945047CT.gov Action of Ketamine in Treatment-Resistant Depression | — | Completed | — | — | — |
NCT01667926CT.gov Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder | — | Completed | — | — | — |
NCT01627782CT.gov A Study of Ketamine in Patients With Treatment-resistant Depression | — | Completed | — | — | — |
NCT01691092CT.gov PET Imaging of mGLuR5 With Drug Challenge | — | Completed | — | — | — |
NCT01700829CT.gov Ketamine in the Treatment of Suicidal Depression | — | Completed | — | — | — |
NCT01582945CT.gov Ketamine Infusion for Treatment-resistant Major Depressive Disorder | — | Completed | — | — | — |
NCT01557712CT.gov Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks | — | Completed | — | — | — |
NCT01573741CT.gov Study of Ketamine as an Antidepressant in Major Depressive Disorder | — | Unknown | — | — | — |
NCT01558063CT.gov Ketamine in the Treatment of Depression | — | Completed | — | — | — |
NCT01870219CT.gov Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy | — | Completed | — | — | — |
NCT01304147CT.gov Intranasal Ketamine in Treatment-Resistant Depression | — | Completed | — | — | — |
NCT01260649CT.gov N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major Depression | — | Terminated | — | — | — |
NCT01135758CT.gov Study of Depression-Ketamine-Brain Function | — | Terminated | — | — | — |
NCT01881763CT.gov Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression | — | Completed | — | — | — |
NCT01309581CT.gov Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression | — | Terminated | — | — | — |
NCT00768430CT.gov Optimization of IV Ketamine for Treatment Resistant Depression | — | Completed | — | — | — |
NCT00646087CT.gov Ketamine Frequency Treatment for Major Depressive Disorder | — | Withdrawn | — | — | — |
NCT00548964CT.gov Continuation Ketamine in Major Depression | — | Completed | — | — | — |
NCT00419003CT.gov Research Study for Major Depressive Disorder: Investigation of Glutamate Medications | — | Completed | — | — | — |
NCT00088699CT.gov Rapid Antidepressant Effects of Ketamine in Major Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone (this asset) | Western University, Canada | Approved | BB · 70 |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Escitalopram | Shanghai 7th People's Hospital | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Traumatic Stress Disorder | — | P4 | BBB · 74 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-o-chlorophenyl-2-methylaminocyclohexanone-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →